J05AG05 - Rilpivirine |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form of nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
A very common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are vomiting, abdominal pain, fatigue and increased transaminase.
Rationale
Rilpivirine has been found to be an activator of hPXR and an inducer of CYP3A4. However, due to high plasma protein binding and a low free plasma concentration this is unlikely to be clinically relevant. No drug-drug interactions with rilpivirine as a perpetrator were found.
Chemical description
Diarylpyrimidine
Therapeutic characteristics
Rilpivirine is an antiretroviral agent indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.
Hepatic exposure
Average steady-state plasma concentration of rilpivirine is 400 nM (Weiss 2013).
Metabolism and pharmakokinetics
Rilpivirine is metabolised by CYP3A4 and the elimination half-life is approximately 45 hours (SPC).
From in vitro studies, rilpivirine has been found to be an inhibitor of CYP3A4, CYP2C19 and CYP2B6 (Weiss 2013), and to be an activator of hPXR and an inducer of CYP3A4 (Sharma 2013, Weiss 2013). However, this is unlikely to be clinically relevant because the plasma protein binding of rilpivirine is so high, 99.7 % (SPC), and the free plasma concentration will therefore be very low, 1.2 nM (Weiss 2013).
Rilpivirine does not affect the pharmacokinetics of ethinylestradiol and norethindorine (substrates of CYP3A4) when co-administrated, which indicates that it is not an inhibitor or an inducer of CYP3A4 (Crauwels 2014 and SPC).
Rilpivirine was not found to have any clinically relevant effect on the exposure of several different co-administrated drugs (Crauvels 2013).
References
- Scientific articles
- Crauwels H, van Heeswijk RP, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013 Apr-Jun;15(2):87-101. PMID 23681436. #4755
- Crauwels HM, van Heeswijk RP, et al. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. Int J Clin Pharmacol Ther. 2014 Feb;52(2):118-28. PMID 24161160. #4756
- Sharma D, Lau AJ, et al. Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors. Biochem Pharmacol. 2013 Jun 1;85(11):1700-11. PMID 23583259. #4757
- Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7. PMID 23428312. #3137
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Edurant). #3136
Similar drugs
© NAPOS 2024